Merck & Co., Inc. (NYSE:MRK) enjoys an impressive 79% institutional backing. Despite a drop in Amgen and Merck stocks following the announcement that RFK Jr. would be heading US healthcare, considerations about the company's stock value persist amid the bio-tech market's unpredictable fluctuations. Merck has recently been involved in various deals and partnerships including a $3.3 billion bispecific antibody deal with LaNova Medicines and a $3.3 billion licensing deal with a Chinese biotech for advanced cancer therapy. Some institutions, such as the Kentucky Retirement Systems Insurance Trust Fund, have reduced their positions in Merck while a few others including Intellectus Partners LLC and Empowered Funds LLC have opted for acquisitions. The robust earnings posted by Merck show the company's business strength but some instances of underperformance and weak projections have led to lowering of guidance. Despite competitors like Bristol Myers Squibb seeing a rise in stock, Merck's undervaluation continues to be a topic of discussion amongst analysts. Notably, strong demand for Keytruda and new drugs has propelled the company's earnings even as HPV vaccine (Gardasil) sales fall. The fluctuating stock trends raise the question; is Merck Stock a buy at $100 or is it overvalued?
Merck Stocks News Analytics from Tue, 30 Jul 2024 07:00:00 GMT to Sat, 16 Nov 2024 14:05:39 GMT -
Rating -1
- Innovation 5
- Information 5
- Rumor -3
